IGF-1 LR3 — Safety, Research, Risks & Legal Status

Not medical advice. IGF-1 LR3 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	long arginine 3 IGF-1, Long R3 IGF-1, insulin-like growth factor 1 LR3
Category	Peptide
not_fda_approved	Research chemical only; no human clinical trials or approved indications
direct_igf1_receptor_activation	Unlike GH secretagogues, it bypasses pituitary regulation and directly activates IGF-1 receptors
hypoglycemia_risk	Acute hypoglycemia is a known pharmacological effect and a serious safety concern
US legal status	IGF-1 LR3 is not approved by the FDA for human use in the United States and is sold as a research chemical not for human consumption, often for cell-culture research. It has no approved medical indication. It is explicitly prohibited at all times in sport under the WADA list as a growth factor.

What is IGF-1 LR3?

IGF-1 LR3 is a modified, longer-acting analog of insulin-like growth factor 1 with an extended half-life due to reduced binding to IGF binding proteins. It directly activates IGF-1 receptors rather than stimulating the pituitary like the GH secretagogues. IGF-1 LR3 is widely used as a research tool in cell biology and animal studies but is not an approved therapeutic.

How it works

IGF-1 LR3 is a 83-amino-acid peptide engineered with a long R3 (arginine) substitution and extended C-terminus that reduces binding to IGF-binding proteins (IGFBPs), markedly extending its circulating half-life from minutes to hours. It directly binds and activates type-1 IGF-1 receptors on target cells, triggering intracellular signaling pathways that promote cell growth, differentiation, and metabolic effects. It also possesses weak insulin-like activity at insulin receptors.

Background & history

IGF-1 LR3 was engineered in the 1990s as a research tool to extend IGF-1's biological half-life and enable more sustained tissue effects in animal studies. It has since become widely used in cell biology research and animal model studies but has never been approved as a human therapeutic. Its pharmacology and potency have made it popular in underground/non-medical use, though this remains illicit.

What the research says

IGF-1 LR3 is widely used as a research reagent to promote cell growth and proliferation in cell culture, and animal research reports anabolic and tissue-growth effects. There is little to no controlled human clinical evidence for performance or body-composition use, so human benefits and risks are poorly characterized. Some animal studies suggest potential metabolic effects, but translation to humans remains speculative.

Reported effects

Reported promotion of cell growth and proliferation in culture
Studied anabolic and tissue-growth effects in animal research
Reported hypoglycemic (blood-sugar-lowering) activity
Studied direct activation of IGF-1 receptors
Reported effects on myofiber hypertrophy in animal models
Studied local growth effects in tissue at site of injection

Dosing & administration (informational)

In animal studies, IGF-1 LR3 has been administered intravenously, subcutaneously, or intramuscularly in doses ranging from micrograms to milligrams per kilogram of body weight, with metabolic and growth effects observed over hours to days. Local injection (e.g., intramuscular) near target tissues can achieve high local concentrations. No human clinical dosing data or studies exist.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Because it directly activates IGF-1 receptors, it can cause hypoglycemia (dangerously low blood sugar), a notable acute risk
Injection carries risks of pain, bruising, infection, and injection-site reactions without sterile technique
Sustained IGF-1 elevation is a theoretical cancer concern, since IGF-1 is a potent growth and proliferation signal, and may promote organ or tissue overgrowth
Prohibited at all times in sport under the WADA list as a growth factor
Sold as a research chemical with no quality assurance, so contamination, mislabeling, and impurity are real risks
Systemic IGF-1 elevation may cause joint pain, carpal tunnel, and other compression neuropathies

Drug & supplement interactions

Insulin and glucose-lowering agents increase hypoglycemia risk
Growth hormone may have synergistic anabolic effects (not studied together in humans)
IGF-binding proteins may sequester or reduce IGF-1 LR3 activity
Thyroid hormone and other growth-promoting agents may amplify tissue-growth effects

Who should avoid it

Insulin-dependent diabetes or blood-glucose dysregulation (hypoglycemia risk)
Active malignancy or cancer history (IGF-1 is a powerful growth signal)
Severe fasting or caloric restriction (exacerbates hypoglycemia risk)
Pregnancy and nursing (unknown teratogenic or developmental effects)
Severe renal or hepatic impairment

How it is commonly combined

IGF-1 LR3 is sometimes combined with GH secretagogues or GH in animal research, though synergistic effects and human safety of such combinations are not established. Combined use of potent growth signals is not recommended and carries compounded risks.

Legal & regulatory. IGF-1 LR3 is not approved by the FDA for human use in the United States and is sold as a research chemical not for human consumption, often for cell-culture research. It has no approved medical indication. It is explicitly prohibited at all times in sport under the WADA list as a growth factor.

Quality & harm reduction

R
e
q
u
i
r
e
a
t
h
i
r
d
-
p
a
r
t
y
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
(
C
O
A
)
f
o
r
a
n
y
p
r
o
d
u
c
t
.
L
o
o
k
f
o
r
H
P
L
C
a
n
d
m
a
s
s
s
p
e
c
t
r
o
m
e
t
r
y
i
d
e
n
t
i
t
y
a
n
d
p
u
r
i
t
y
d
a
t
a
.
E
n
d
o
t
o
x
i
n
(
L
A
L
)
t
e
s
t
i
n
g
i
s
i
m
p
o
r
t
a
n
t
f
o
r
a
n
y
i
n
j
e
c
t
a
b
l
e
p
e
p
t
i
d
e
.
U
s
e
s
t
e
r
i
l
e
r
e
c
o
n
s
t
i
t
u
t
i
o
n
a
n
d
c
o
l
d
s
t
o
r
a
g
e
,
a
s
I
G
F
-
1
a
n
a
l
o
g
s
a
r
e
s
e
n
s
i
t
i
v
e
t
o
d
e
g
r
a
d
a
t
i
o
n
a
n
d
m
u
s
t
r
e
m
a
i
n
s
t
e
r
i
l
e
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

How is IGF-1 LR3 different from GH peptides?

GH secretagogues stimulate the pituitary to release growth hormone, whereas IGF-1 LR3 directly activates IGF-1 receptors, bypassing the natural feedback loop.

Why is hypoglycemia a concern?

IGF-1 has insulin-like activity, so research reports it can lower blood glucose, which can become dangerous, especially when combined with insulin or fasting.

What dose is safe?

We do not provide human dosing guidance for unapproved research chemicals, particularly given the hypoglycemia and growth-signal risks.

Can IGF-1 LR3 cause cancer?

Sustained IGF-1 elevation is a theoretical cancer concern because IGF-1 is a potent cell-growth and proliferation signal. Long-term effects in humans are unknown.

Is IGF-1 LR3 legal?

It is not approved for human use and is sold as a research chemical. It is explicitly banned in sport under the WADA list as a growth factor.

References & further reading

PubMed: IGF-1 LR3 insulin-like growth factor cell growth
PubMed: IGF-1 LR3 anabolic effects animal models
PubMed: IGF-1 LR3 hypoglycemia insulin-like activity
WADA Prohibited List: growth factors IGF-1
PubMed: IGF binding proteins IGF-1 bioavailability